To: | Aurobindo Pharma Ltd (arodriguez@bpslaw.com) |
Subject: | U.S. Trademark Application Serial No. 88361892 - AFIRMELLE - N/A |
Sent: | December 12, 2019 05:27:52 PM |
Sent As: | ecom124@uspto.gov |
Attachments: |
United States Patent and Trademark Office (USPTO)
Office Action (Official Letter) About Applicant’s Trademark Application
U.S. Application Serial No. 88361892
Mark: AFIRMELLE
|
|
Correspondence Address: |
|
Applicant: Aurobindo Pharma Ltd
|
|
Reference/Docket No. N/A
Correspondence Email Address: |
|
EXAMINER’S AMENDMENT
Issue date: December 12, 2019
Application has been amended as shown below. As agreed to by Adam Rodriguez on December 10, 2019, the examining attorney has amended the application as shown below. Please notify the examining attorney immediately of any objections. TMEP §707. Otherwise, no response is required. Id. In addition, applicant is advised that amendments to the goods and/or services are permitted only if they clarify or limit them; amendments that add to or broaden the scope of the goods and/or services are not permitted. 37 C.F.R. §2.71(a).
The identification of goods is amended to read as follows:
“Prescription contraceptive preparations” in Class 5.
See TMEP §§1402.01, 1402.01(e).
All issues with the application have been resolved.
/Chandel Boozer/
Examining Attorney
Law Office 124
571-272-7272
chandel.boozer@uspto.gov